Prof. Ma Jun Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

Prof. Ma Jun Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

Local time on December 9th, the eagerly awaited 65th American Society of Hematology (ASH) Annual Meeting officially kicked off in San Diego, USA. The Oncology Insight reporting team delved into the forefront, witnessing the impressive presence of "The Voice of China" on the international stage. ASH is one of the largest and most comprehensive international academic conferences in the field of hematology globally, attracting numerous experts and scholars from around the world each year, including a significant representation from China. On the second day of the conference, we had the privilege of interviewing Professor Ma Jun, a leading figure in the field of hematology in China and the Director of the Harbin Institute of Hematology and Oncology. He shared his insights and highlights of this year's conference. Below is Professor Ma Jun's perspective:
2023 ASH丨Professor Jiang Qian: Discussing Drug Resistance in Chronic Myeloid Leukemia (CML) Treatment and the Value of Novel TKIs

2023 ASH丨Professor Jiang Qian: Discussing Drug Resistance in Chronic Myeloid Leukemia (CML) Treatment and the Value of Novel TKIs

The 65th Annual Meeting of the American Society of Hematology (ASH) recently concluded, with significant contributions in the field of Chronic Myeloid Leukemia (CML) treatment. Professor Jiang Qian and her team from Peking University People's Hospital presented multiple studies, with abstracts 867 and 869 selected for oral presentations. These reports highlighted the potential of TGRX-678 and Olverembatinib in CML treatment and overcoming drug resistance. "Hematology Frontier" had the privilege of interviewing Professor Jiang Qian on these topics.